WHO ARE WE :
Invitrocue is an innovative life sciences company that supports decision making for the healthcare and pharmaceutical industry using our proprietary 3D cell culture technology. We were founded in 2012, aimed to commercialize proprietary 3D cell culture technology developed at A*STAR’s Institute of Bioengineering and Nanotechnology in Singapore, Massachusetts Institute of Technology Cambridge, and the Genome Institute of Singapore. In 2019, we developed and started providing a 3D Patient-Derived Organoids Technology under the trade name of Onco-PDO Test as a result of a partnership with A*STAR´s Genome Institute of Singapore. In 2019, we developed a humanized mice model for preclinical research in partnership with A*STAR’s Institute of Molecular and Cell Biology (IMCB).
PRODUCTS AND SERVICES WE ARE OFFERING INCLUDE :-
Onco-PDO™ Test
Preclinical efficacy and safety Assessment
Humanized technologies
OUR OBJECTIVE
To develop predictive in vitro and in vivo models that enable the healthcare and pharmaceutical industry to create better, faster and more affordable disease treatments for a healthier society.